155 related articles for article (PubMed ID: 35579627)
1. How Should the Effects of CFTR Modulator Therapy on Cystic Fibrosis Lung Disease Be Monitored?
Ben-Meir E; Grasemann H
Am J Respir Crit Care Med; 2022 Aug; 206(3):240-242. PubMed ID: 35579627
[No Abstract] [Full Text] [Related]
2. Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
Dooney M; Saba T
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423592
[No Abstract] [Full Text] [Related]
3. Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme.
Burgel PR
Eur Respir J; 2024 Feb; 63(2):. PubMed ID: 38423591
[No Abstract] [Full Text] [Related]
4. Gathering real-world compassionate data to expand eligibility for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with N1303K or other rare
Burgel PR; Sermet-Gaudelus I; Girodon E; Kanaan R; Le Bihan J; Remus N; Ravoninjatovo B; Grenet D; Porzio M; Houdouin V; Le Clainche-Viala L; Durieu I; Nove-Josserand R; Languepin J; Coltey B; Guillaumot A; Audousset C; Chiron R; Weiss L; Fajac I; Da Silva J; Martin C;
Eur Respir J; 2024 Jan; 63(1):. PubMed ID: 38242629
[No Abstract] [Full Text] [Related]
5. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on Lung Clearance Index and Magnetic Resonance Imaging in Patients with Cystic Fibrosis and One or Two
Graeber SY; Renz DM; Stahl M; Pallenberg ST; Sommerburg O; Naehrlich L; Berges J; Dohna M; Ringshausen FC; Doellinger F; Vitzthum C; Röhmel J; Allomba C; Hämmerling S; Barth S; Rückes-Nilges C; Wielpütz MO; Hansen G; Vogel-Claussen J; Tümmler B; Mall MA; Dittrich AM
Am J Respir Crit Care Med; 2022 Aug; 206(3):311-320. PubMed ID: 35536314
[No Abstract] [Full Text] [Related]
6. New Drug Hailed as Major Breakthrough in Cystic Fibrosis.
Am J Med Genet A; 2020 Jan; 182(1):8-9. PubMed ID: 31825178
[No Abstract] [Full Text] [Related]
7. Questions and Answers? Depression Symptoms Associated with Elexacaftor/Tezacaftor/Ivacaftor Treatment for Cystic Fibrosis.
Lee TWR; Duff AJA
Am J Respir Crit Care Med; 2024 Feb; 209(3):239-241. PubMed ID: 38113403
[No Abstract] [Full Text] [Related]
8. Is Elexacaftor/Tezacaftor/Ivacaftor Effective in Treating Sinonasal Disease in Patients with Cystic Fibrosis?
Merrill TB; Tyes J; Woodard TD
Laryngoscope; 2024 Feb; 134(2):501-503. PubMed ID: 37548273
[No Abstract] [Full Text] [Related]
9. The march towards CFTR modulator access for all people with CF: The end of the beginning.
VanDevanter DR
J Cyst Fibros; 2021 Mar; 20(2):185-187. PubMed ID: 33495080
[No Abstract] [Full Text] [Related]
10. Elexacaftor/tezacaftor/ivacaftor for CFTR variants giving rise to diagnostic uncertainty: Personalised medicine or over-medicalisation?
Salvatore D; Pepe A; Carnovale V; Majo F; Padoan R; Quattrucci S; Salvatore M; Taruscio D; Amato A; Ferrari G; Campagna G
J Cyst Fibros; 2022 May; 21(3):544-548. PubMed ID: 34583889
[No Abstract] [Full Text] [Related]
11. Elexacaftor/tezacaftor/ivacaftor in children aged 6-11 years with cystic fibrosis, at least one F508DEL allele, and advanced lung disease: A 24-week observational study.
Salvatore D; Cimino G; Troiani P; Bignamini E; Esposito I; Leonetti G; Zanda M; Manunza D; Pepe A
Pediatr Pulmonol; 2022 Sep; 57(9):2253-2256. PubMed ID: 35577767
[No Abstract] [Full Text] [Related]
12. Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Advanced Cystic Fibrosis Lung Disease.
Djavid AR; Thompson AE; Irace AL; Gusman E; Altman K; DiMango EA; Keating CL
Ann Am Thorac Soc; 2021 Nov; 18(11):1924-1927. PubMed ID: 34000224
[No Abstract] [Full Text] [Related]
13. VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Keating D; Marigowda G; Burr L; Daines C; Mall MA; McKone EF; Ramsey BW; Rowe SM; Sass LA; Tullis E; McKee CM; Moskowitz SM; Robertson S; Savage J; Simard C; Van Goor F; Waltz D; Xuan F; Young T; Taylor-Cousar JL;
N Engl J Med; 2018 Oct; 379(17):1612-1620. PubMed ID: 30334692
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of elexacaftor/tezacaftor/ivacaftor in patients with cystic fibrosis and advanced lung disease.
O'Shea KM; O'Carroll OM; Carroll C; Grogan B; Connolly A; O'Shaughnessy L; Nicholson TT; Gallagher CG; McKone EF
Eur Respir J; 2021 Feb; 57(2):. PubMed ID: 33154033
[No Abstract] [Full Text] [Related]
15. Olfaction before and after initiation of elexacaftor-tezacaftor-ivacaftor in a cystic fibrosis cohort.
Bacon DR; Stapleton A; Goralski JL; Ebert CS; Thorp BD; Nouraie M; Shaffer AD; Senior BA; Lee SE; Zemke AC; Kimple AJ
Int Forum Allergy Rhinol; 2022 Feb; 12(2):223-226. PubMed ID: 34709729
[No Abstract] [Full Text] [Related]
16. Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.
Wielpütz MO; Mall MA
Eur Respir J; 2024 Mar; 63(3):. PubMed ID: 38548272
[No Abstract] [Full Text] [Related]
17. Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor.
Lowry S; Mogayzel PJ; Oshima K; Karnsakul W
J Cyst Fibros; 2022 Mar; 21(2):e99-e101. PubMed ID: 34275759
[No Abstract] [Full Text] [Related]
18. Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis.
McKinzie CJ; Doligalski CT; Lobritto SJ; Coakley RD; Gower WA
J Cyst Fibros; 2022 Mar; 21(2):227-229. PubMed ID: 34384711
[No Abstract] [Full Text] [Related]
19. Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis.
Anderson A; McCoy L; Pettit RS; Wright BA; Lubsch L
Pediatr Pulmonol; 2021 Dec; 56(12):4053-4054. PubMed ID: 34499822
[No Abstract] [Full Text] [Related]
20. Elexacaftor/tezacaftor/ivacaftor can rescue pancreatic function in F508del homozygous children.
Nathan N; Thouvenin G; Dubern B; Corvol H
Pediatr Pulmonol; 2024 Mar; 59(3):788-790. PubMed ID: 38088210
[No Abstract] [Full Text] [Related]
[Next] [New Search]